FibroGen's (FGEN) Peak EU Roxa Sales Could be as High as $900M - BofA Securities
Tweet Send to a Friend
BofA Securities analyst Jason Gerberry reiterated a Buy rating and $43.00 price target on FibroGen (NASDAQ: FGEN) after the company's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
